All In Biotech

Drug Trial Radar · NCT02718261

Sup-Icu RENal (SIREN)

Sup-Icu RENal (SIREN) - a Sub-analysis of the Prospective SUP (Stress Ulcer Prophylaxis)-ICU Trial on the Risk of GI- Bleeding in ICU Patients Receiving Renal Replacement Therapy

Last checked: Nov 19, 2026Latest source record: Sep 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 3,350 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,350

Actual

Start

Feb 2016

Primary completion

Sep 2018

Study completion Sep 2018

Sponsor

Lead sponsor
Insel Gruppe AG, University Hospital BernAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Copenhagen University Hospital, Rigshospitalet
First posted
Mar 24, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Other
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Data show that episodes of bleeding may often be observed in critically ill patients with dialysis-dependent acute renal failure (ARF) on renal replacement therapy (RRT). From a clinical perspective, patients with dialysis-dependent ARF and end-stage renal disease (ESRD) may be considered a high risk population in regard to e.g. development of gastrointestinal (GI-) bleeding. In the current prospective subanalysis "SIREN" of the randomized placebo-controlled clinical trial "SUP-ICU" (NCT02467621), the investigators seek to elucidate whether the subpopulation of critically ill patients with acute kidney injury requiring renal replacement therapy (RRT) benefit from prophylactic treatment with a proton-pump-inhibitor such as pantoprazole.

Conditions

  • Critical Illness
  • Acute Kidney Injury
  • End-stage Renal Disease
  • Renal Replacement Therapy
  • Proton Pump Inhibitor

Interventions

  • PantoprazoleDrug

  • Saline 0.9% (matching placebo)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of patients with clinically important GI bleedingTime frame: 90 days or length of ICU stay, as applicable

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Rigshospitalet

    Copenhagen, Denmark

  • Dept. of Intensive Care Medicine, University of Bern,

    Bern, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.